biostudies-literatureUnknown5(7)O'Brien TJ<h4>Importance</h4>Cannabidiol has shown efficacy in randomized clinical trials for drug-resistant epilepsy in specific syndromes that predominantly affect children. However, high-level evidence for the efficacy and safety of cannabidiol in the most common form of drug-resistant epilepsy in adults, focal epilepsy, is lacking.<h4>Objective</h4>To investigate the efficacy, safety, and tolerability of transdermally administered cannabidiol in adults with drug-resistant focal epilepsy.<h4>Design, setting, and participants</h4>A randomized, double-blind, placebo-controlled, multicenter clinical trial at 14 epilepsy trial centers in Australia and New Zealand. Participants were adults with drug-resistant focal epilepsy receiving a stable regimen of up to 3 antiseizure medications. Data were analyJAMA network opene2220189https://www.ebi.ac.uk/biostudies/studies/S-EPMC9270696biostudies-literatureAdjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.PMC9270696D'Souza WSebree TBRosemergy IBergin PFrasca JAnderson TReutens DNikpour ASeneviratne UMessenheimer JAGutterman DLFrench JAO'Brien TJWijayath MSTAR 1/STAR 2 Study GroupBonn-Miller MOPatrikios PBerkovic SFKwan PAsztely FfalseAdjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.<h4>Importance</h4>Cannabidiol has shown efficacy in randomized clinical trials for drug-resistant epilepsy in specific syndromes that predominantly affect children. However, high-level evidence for the efficacy and safety of cannabidiol in the most common form of drug-resistant epilepsy in adults, focal epilepsy, is lacking.<h4>Objective</h4>To investigate the efficacy, safety, and tolerability of transdermally administered cannabidiol in adults with drug-resistant focal epilepsy.<h4>Design, setting, and participants</h4>A randomized, double-blind, placebo-controlled, multicenter clinical trial at 14 epilepsy trial centers in Australia and New Zealand. Participants were adults with drug-resistant focal epilepsy receiving a stable regimen of up to 3 antiseizure medications. Data were analy2022-01-01T00:00:00Z2022 Jul2025-04-27T00:06:45.964Z2025-02-18T22:39:58.974ZS-EPMC92706963580237510.1001/jamanetworkopen.2022.20189